Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 36 NSCLC 9 Adenocarcinoma of Lung 5 Meningeal Carcinomatosis 4 Lung Neoplasms 4 Brain Neoplasms 3 Respiratory Tract Neoplasms 1 Pleural Effusion, Malignant 1 Non Small Cell Lung Cancer NSCLC 1 Neoplasm, Residual 1 Multiple Primary Lung Cancers 1 Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer 1 EGF-R Positive Non-Small Cell Lung Cancer 1 Carcinoma 1 Bronchial Neoplasms 1 Advanced Non-small Cell Lung Cancer 1 Advanced NSCLC Patients With T790M 1 Advanced NSCLC 1 Advanced Lung Cancer 1 Adenocarcinoma 1

Interventions

Carboplatin 24 Pemetrexed 18 Cisplatin 17 Paclitaxel 14 pembrolizumab 13 Gemcitabine 8 osimertinib 7 durvalumab 6 Docetaxel 6 Nivolumab 5 Erlotinib Hydrochloride 5 130-nm albumin-bound paclitaxel 5 capmatinib 3 brigatinib 3 anlotinib 3 Gefitinib 3 Drug Therapy 3 vosaroxin 2 volociximab 2 sintilimab 2 pralsetinib 2 ensartinib 2 atezolizumab 2 aflibercept 2 Surgical Procedures, Operative 2 Radiotherapy, Intensity-Modulated 2 Radiotherapy 2 Radiation 2 Oncolytic Virotherapy 2 Ipilimumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma × aflutinib × Thoracic × Clear all

NCT04401059 2023-12-27

SELECT-2

Hangzhou Normal University

Phase 4 Unknown

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡